0001493152-23-040514.txt : 20231113 0001493152-23-040514.hdr.sgml : 20231113 20231113161526 ACCESSION NUMBER: 0001493152-23-040514 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 231398932 BUSINESS ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
false 0001642375 0001642375 2023-11-13 2023-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2023

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   47-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 13, 2023, Guardion Health Sciences, Inc. (the “Company”) issued a press release announcing financial results for the three months and nine months ended November 13, 2023. The text of the press release is furnished as Exhibit 99.1 to this current report.

 

The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Exhibit
99.1   Press release dated November 13, 2023
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
Date: November 13, 2023    
  By: /s/ Jan Hall
  Name: Jan Hall
  Title: Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Guardion Health Sciences Announces Financial Results

for the Three Months and Nine Months Ended September 30, 2023

 

Viactiv® Generated Net Revenues of Approximately $3.3 Million for the Three Months Ended September 30, 2023, an increase of 27% over the Three Months Ended September 30, 2022

 

HOUSTON, TEXAS – November 13, 2023 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and nine months ended September 30, 2023. The Company also provided a corporate update to stockholders.

 

Financial highlights for the three months ended September 30, 2023 include the following:

 

  ● Total revenue was $3,337,190 for the three months ended September 30, 2023, as compared to $2,663,550 for the three months ended September 30, 2022, an increase of $673,640 or 25.3%. The increase in total revenue was driven primarily by sales growth of the Viactiv® product line, which accounted for approximately 97.5% and 96.2% of the Company’s total revenue for the three months ended September 30, 2023 and 2022, respectively. Drivers of the sales increase included resolution of the short-term impact of a third-party warehouse expansion which had resulted in carry over of retail shipments from June into July 2023, in combination with strong shipments to Amazon, plus additional distribution of the Company’s Omega Boost® product.
     
  ● Gross profit was $1,460,252 for the three months ended September 30, 2023, as compared to $1,088,184 for the three months ended September 30, 2022, an increase of $372,068 or 34.2%. The increase in gross profit was primarily attributable to the increase in sales from the Viactiv® product line.
     
  ● Gross margin for the three months ended September 30, 2023 was 43.8%, as compared to 40.9% for the three months ended September 30, 2022, an increase of 2.9 percentage points, which was driven by cost of goods favorability, such as lower transportation costs, and higher sales in 2023.
     
  ● Total operating expenses for the three months ended September 30, 2023 were $2,233,166, as compared to $2,827,578 for the three months ended September 30, 2022, a decrease of $594,412 or 21.0%. The variance was attributable to a combination of factors, including the amortization of intangible assets in 2022 that was no longer occurring in 2023, reduced payroll expense, lower executive stock compensation expense and lower consultant fees.

 

1

 

 

  ● Loss from operations for the three months ended September 30, 2023 decreased to $(772,914), as compared to $(1,739,394) for the three months ended September 30, 2022, a reduction of $966,480 or 55.6%.
     
  ● As a result of the aforementioned factors, including the non-cash gain from the change in fair value of the warrant derivative liability of $1,050,800 and $873,200 for the three months ended September 30, 2023 and 2022, respectively, net income was $372,633 for the three months ended September 30, 2023, as compared to a net loss of $822,912 for the three months ended September 30, 2022.
     
  ● Basic and diluted net income for the three months ended September 30, 2023 was $0.29 per share, as compared to basic and diluted net loss of $(0.67) per share for the three months ended September 30, 2022, based on 1,273,486 weighted average common shares outstanding in 2023 and 1,232,016 weighted average common shares outstanding in 2022.
     
  ● Cash used in operations for the three months ended September 30, 2023 was $766,581, as compared to $1,282,141 for the three months ended September 30, 2022.

 

Financial highlights for the nine months ended September 30, 2023 include the following:

 

  ● Total revenue was $9,312,695 for the nine months ended September 30, 2023, as compared to $8,323,382 for the nine months ended September 30, 2022, an increase of $989,313 or 11.9%. The increase in total revenue was driven by increased sales of the Viactiv® product line, which accounted for approximately 97.2% and 96.2% of the Company’s total revenue for the nine months ended September 30, 2023 and 2022, respectively. Drivers of the sales increase included resolution of the short-term impact of a third-party warehouse expansion which resulted in carry over of retail shipments from June into July 2023, in combination with strong shipments to Amazon, plus additional distribution of the Company’s Omega Boost® product line.
     
  ● Gross profit was $4,044,821 for the nine months ended September 30, 2023, as compared to $3,584,185 for the nine months ended September 30, 2022, an increase of $460,636 or 12.9%. The increase in gross profit was primarily attributable to the increase in sales from the Viactiv® product line.
     
  ● Gross margin for the nine months ended September 30, 2023 was 43.4%, as compared to 43.1% for the nine months ended September 30, 2022, an increase of 0.3 percentage points, which was driven by cost of goods favorability, such as the realization of lower supply chain transportation costs that began May 2023, and higher sales.
     
  ● Total operating expenses for the nine months ended September 30, 2023 were $7,294,388, as compared to $9,655,205 for the nine months ended September 30, 2022, a decrease of $2,360,817 or 24.5%. The variance was attributable to a combination of factors, including including the amortization of intangible assets in 2022, reduced payroll expense, insurance, and professional fees and consulting fees.

 

2

 

 

  ● Loss from operations for the nine months ended September 30, 2023 decreased to $(3,249,567), as compared to $(6,071,020) for the nine months ended September 30, 2022, a reduction of $2,821,453 or 46.5%.
     
  ● As a result of the aforementioned factors, including the non-cash gain from the change in fair value of the warrant derivative liability of $2,693,600 and $3,548,300 for the nine months ended September 30, 2023 and 2022, respectively, net loss was $266,687 for the nine months ended September 30, 2023, as compared to a net loss of $2,468,262 for the nine months ended September 30, 2022.
     
  ● Basic and diluted net loss for the nine months ended September 30, 2023 was $(0.21) per share, as compared to basic and diluted net loss of $(2.27) per share for the nine months ended September 30, 2022, based on 1,273,249 weighted average common shares outstanding in 2023 and 1,083,924 weighted average common shares outstanding in 2022.
     
  ● Cash used in operations for the nine months ended September 30, 2023 was $3,052,293, as compared to $6,082,906 for the nine months ended September 30, 2022. The decrease of $3,030,613 in cash used by operating activities was primarily due to a reduction in general and administrative expenses.
     
  ● As of September 30, 2023, the Company had unrestricted cash and cash equivalents of $7,657,309 and net working capital of $11,407,975.

 

Additional significant events that occurred during the three months and nine months ended September 30, 2023, included the following:

 

  ● Alantra LLC was retained as the Company’s exclusive financial advisor to implement a strategic review to solicit and evaluate alternatives to maximize stockholder value in the near-term, which review is on-going.
     
  ● Jan Hall was appointed President and CEO, effective June 19, 2023, replacing Bret Scholtes.
     
  ● Katie Cox was appointed as Chief Accounting Officer, effective July 25, 2023, replacing Jeffrey Benjamin.

 

Jan Hall, Guardion’s President and Chief Executive Officer, commented, “We are pleased with the progress made during the quarter which was driven by strong topline growth combined with improved operating margins and a reduced cash burn.”

 

“We are continuing our efforts to build a clinical nutrition platform and the Viactiv® brand. We are also continuing our strategic review process with Alantra, LLC (“Alantra”), our exclusive financial advisor, to evaluate opportunities to maximize stockholder value in the near-term.

 

3

 

 

“In the meantime, we believe our market position, consumer loyalty and the extendability of the Viactiv® brand, combined with our current operating business strategy, provide us with a viable platform from which to leverage our resources to continue our efforts to grow operations, improve financial performance and maximize stockholder value,” concluded Ms. Hall.”

 

Financial Results

 

Additional information with respect to the Company’s business, operations and financial condition as of and for the three months and nine months ended September 30, 2023 is contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, which has been filed with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

 

About Guardion Health Sciences, Inc.

 

Guardion Health Sciences, Inc. (Nasdaq: GHSI) is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. Information and risk factors with respect to Guardion and its business may be obtained in the Company’s filings with the SEC at www.sec.gov.

 

Forward-Looking Statement Disclaimer

 

With the exception of the historical information contained in this news release, the matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

 

These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to fund its business plan, the impact of the Company’s exploration of strategic alternatives, any replacement and integration of new management team members, the implementation of new financial, management, accounting and business software systems, the identification and integration of possible acquisition targets and suitors, the impact of the COVID-19 pandemic, supply chain disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For more information about Guardion Health Sciences, Inc., Contact:

 

investors@guardionhealth.com

 

Phone: 1-800 873-5141 Ext 208

 

4

 

 EX-101.SCH 3 ghsi-20231113.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ghsi-20231113_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ghsi-20231113_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 13, 2023
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 47-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2023-11-13 2023-11-13 iso4217:USD shares iso4217:USD shares false 0001642375 8-K 2023-11-13 GUARDION HEALTH SCIENCES, INC. DE 001-38861 47-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false false false false Common Stock, par value $0.001 per GHSI NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ghsi-20231113.xsd ghsi-20231113_lab.xml ghsi-20231113_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20231113", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ghsi-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ghsi-20231113_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20231113_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://guardionhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-23-040514-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040514-xbrl.zip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end